binimetinib
Ligand Summary
Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cellfree assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models.
UNII: 181R97MR71
PubChem: 10288191
Guide to Pharmacology: 7921
ChEMBL: CHEMBL3187723
DrugCentral: 5290
LyCHI: T5F4WDQXB4V3
Target Activities
4 Activities
Items per page:
10
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | INHIBITOR | |||||
IC50 | INHIBITOR | |||||